Conclusion
Nebulised UFH has a strong scientific and biological rationale, and warrants urgent investigation of its therapeutic potential, for COVID-19. This investigator-initiated international individual patient data meta-trial of randomised controlled trials and early phase studies investigates the efficacy and safety of nebulised UFH, on relevant outcomes in patients who are hospitalised for COVID-19. Our pre-specified meta-trial protocol and statistical analysis plan was prepared before completion of patient recruitment and data collection. The protocol provides a detailed description of the principles and methods for analysing and reporting the trial results and is in keeping with best research practice.